Browsing by Author Robinson, Bridget

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 2 of 2
Issue DateTitleAuthor(s)Citation
2010Capecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study.Gebski, Val; Simes, Robert John; Stockler, Martin; Zannino, Diana; Ackland, Stephen P.; Broad, Adam; Chua, Yu Jo; Cummins, Michelle; Cunningham, David; Forgeson, Garry; Ganju, Vinod; Price, Timothy; Robinson, Bridget; Saunders, M; Tebbutt, Niall C; van Hazel, Guy; Wilson, Kate; Zalcberg, J; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreCapecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study., Journal of Clinical Oncology (Online), vol.28, 19,pp 3191-3198
2016SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal CancerGebski, Val; et al, Various; Ferguson, Tom; Findlay, Michael; Hazel, Guy; Heinemann, Volker; Peeters, Marc; Perez, D; Ricke, Jens; Robinson, Bridget; Sharma, Navesh; Strickland, A. H.; NH&MRC Clinical Trials CentreSIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.34, 15, 2016,pp 1723-1731